ArticleBMC cancer2026
Combining fruquintinib with TAS-102 as a promising strategy: antitumor activity in preclinical colorectal and gastric cancer xenograft models.
Article in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe combination of bevacizumab and TAS-102 has emerged as a treatment option for metastatic colorectal cancer (CRC). Bevacizumab is an anti-VEGF-A antibody, and TAS-102 is a cytotoxic nucleotide analog. Recently, fruquintinib, an oral, potent and highly selective inhibitor of all three vascular endothelial growth factor receptors (VEGFRs), has been approved for the treatment of chemorefractory CRC. The purpose of this study was to investigate the combined antitumor activity of fruquintinib and TAS-102 in CRC and gastric cancer (GC) models and to reveal possible mechanisms to explain the combined effects.
methodsIn vitro angiogenic and lymphangiogenic activities were studied by tube formation assays using HUVECs and HDLECs, respectively. Protein expression was measured by Western blot analysis. Intratumor drug concentrations were determined by liquid chromatography-tandem mass spectrometry analysis. Antitumor activity was studied in xenograft models.
resultsFruquintinib inhibited tube formation in both HUVECs and HDLECs. Trifluridine, an anti-neoplastic component of TAS-102, potentiated the inhibition of tube formation by fruquintinib in HUVECs but not in HDLECs. Suppression of VEGFR downstream signaling, together with induction of DNA damage response, was observed in HUVECs treated with the fruquintinib plus trifluridine combination. In an HT-29 CRC xenograft model, the intratumor levels of trifluridine and its active metabolites were higher following the fruquintinib plus TAS-102 combination treatment than following TAS-102 monotherapy. Antitumor studies demonstrated that the combination of fruquintinib and TAS-102 suppressed tumor growth more potently than individual agents in HT-29 and COLO-205 CRC xenograft models. The combined effect was comparable to that of bevacizumab plus TAS-102 in CRC models and was also observed in SC-2-JCK and MKN45 GC xenograft models. The addition of fruquintinib did not increase body weight loss caused by TAS-102 alone.
conclusionsThe combination of fruquintinib and TAS-102 improved antitumor activity in CRC and GC xenograft models, with in vitro evidence of enhanced anti-angiogenic activity of fruquintinib by trifluridine and ex vivo evidence of an increased amount of intratumor trifluridine with fruquintinib. Our data support testing the combination of fruquintinib and TAS-102 in clinical studies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.